NOD2 and neoplasm: Our findings are consistent with previous studies, which reported that a combination of NOD2 agonists with interferon [64] and tumor microparticle vaccine [65] activated NOD2 signaling, generated an anti-tumor immune response, and inhibited melanoma growth.